![conference banner](/images/conference-banner.jpeg)
Abstract
The induction of G1 cell cycle arrest and apoptosis by second-generation selenium compounds (e.g., methylselenol precursors such as methylseleninic acid, MSeA) may contribute to their anti-cancer activities. We have documented previously induction of G1 arrest and apoptosis by MSeA in association with upregulation of cyclin-dependent kinase inhibitor (CDKI) proteins P21Cip1 and/or P27Kip1 in DU145 prostate cancer cells. However, whether these CDKIs play a critical mediator role in G1 arrest and apoptosis by MSeA has not been addressed. In the present work, we show exposure of p53-mutant DU145 cells to sub-apoptotic concentrations of MSeA induced p21cip1 mRNA (3 h) and protein (6 h) much faster than p27kip1 mRNA (12 h) and protein (12 h). Knocking down of P21Cip1 by siRNA completely abolished G1 arrest induction by MSeA in DU145 cells, yet si-p27 RNA had no attenuation effect on the G1 arrest. Depletion of P21Cip1 alone or both P21Cip1 and P27Kip1 increased MSeA-induced caspase-mediated apoptosis. Immunoprecipitation detected increased binding of P21Cip1 to CDK2 and CDK6 in MSeA-exposed DU145 cells. In DU145 xenografts from mice acutely treated with MSeA p.o., the induction of P21Cip1 was observed at 72 h of daily exposure. In p53-wild type LNCaP PCa cells and p53-null PC-3 PCa cells, MSeA modestly and transiently upregulated P21Cip1 protein level, subsiding to basal level by 24 h, without affecting P27Kip1 abundance in the same duration. Si-p21 RNA knockdown in these cells have only a partial effect to reverse G1 arrest induction by MSeA. Together, our data support persistent, p53- independent, P21Cip1 induction as a critical mediator of MSeA-induced G1 arrest in DU145 PCa cells, however, P21Cip1 induction and G1 arrest were not necessary for, and may antagonize, caspase-mediated apoptosis.
Keywords: Selenium, G1 arrest, P21Cip1, siRNA knockdown, prostate cancer
Current Cancer Drug Targets
Title: Persistent P21Cip1 Induction Mediates G1 Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells
Volume: 10 Issue: 3
Author(s): Z. Wang, H.-J. Lee, Y. Chai, H. Hu, L. Wang, Y. Zhang, C. Jiang and J. Lu
Affiliation:
Keywords: Selenium, G1 arrest, P21Cip1, siRNA knockdown, prostate cancer
Abstract: The induction of G1 cell cycle arrest and apoptosis by second-generation selenium compounds (e.g., methylselenol precursors such as methylseleninic acid, MSeA) may contribute to their anti-cancer activities. We have documented previously induction of G1 arrest and apoptosis by MSeA in association with upregulation of cyclin-dependent kinase inhibitor (CDKI) proteins P21Cip1 and/or P27Kip1 in DU145 prostate cancer cells. However, whether these CDKIs play a critical mediator role in G1 arrest and apoptosis by MSeA has not been addressed. In the present work, we show exposure of p53-mutant DU145 cells to sub-apoptotic concentrations of MSeA induced p21cip1 mRNA (3 h) and protein (6 h) much faster than p27kip1 mRNA (12 h) and protein (12 h). Knocking down of P21Cip1 by siRNA completely abolished G1 arrest induction by MSeA in DU145 cells, yet si-p27 RNA had no attenuation effect on the G1 arrest. Depletion of P21Cip1 alone or both P21Cip1 and P27Kip1 increased MSeA-induced caspase-mediated apoptosis. Immunoprecipitation detected increased binding of P21Cip1 to CDK2 and CDK6 in MSeA-exposed DU145 cells. In DU145 xenografts from mice acutely treated with MSeA p.o., the induction of P21Cip1 was observed at 72 h of daily exposure. In p53-wild type LNCaP PCa cells and p53-null PC-3 PCa cells, MSeA modestly and transiently upregulated P21Cip1 protein level, subsiding to basal level by 24 h, without affecting P27Kip1 abundance in the same duration. Si-p21 RNA knockdown in these cells have only a partial effect to reverse G1 arrest induction by MSeA. Together, our data support persistent, p53- independent, P21Cip1 induction as a critical mediator of MSeA-induced G1 arrest in DU145 PCa cells, however, P21Cip1 induction and G1 arrest were not necessary for, and may antagonize, caspase-mediated apoptosis.
Export Options
About this article
Cite this article as:
Wang Z., Lee H.-J., Chai Y., Hu H., Wang L., Zhang Y., Jiang C. and Lu J., Persistent P21Cip1 Induction Mediates G1 Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells, Current Cancer Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/156800910791190238
DOI https://dx.doi.org/10.2174/156800910791190238 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating Aminopeptidase Activities in Men and Women with Essential Hypertension
Current Medicinal Chemistry Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Synergetic Bitherapy in Mice with Xenografts of Human Prostate Cancer Using a Methional Mimic (METLICO) and an Aldehyde Dehydrogenase 3 Inhibitor (MATE): Systemic Intraperitoneal (IP) and Targeted Intra-Tumoral (IT) Administration
Current Medicinal Chemistry Molecular Modelling, Design, Synthesis and Biochemical Evaluation of a Range of Non-Steroidal Thiosemicarbazone-Based Inhibitors of Estrone Sulfatase (ES) - A Potential Insight into the Action of a Range of Allosteric Inhibitors of ES
Letters in Drug Design & Discovery Natural Thiazoline-Based Cyclodepsipeptides from Marine Cyanobacteria: Chemistry, Bioefficiency and Clinical Aspects
Current Medicinal Chemistry Amino Acid Transporter ATB0,+ as a Delivery System for Drugs and Prodrugs
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets The Immune Protective Effect of the Mediterranean Diet against Chronic Low-grade Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets BTX AgilePulse<sup>TM</sup> System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine
Current Gene Therapy Engineering of Escherichia coli for Lycopene Production Through Promoter Engineering
Current Pharmaceutical Biotechnology Microfilament Actin Remodeling as a Potential Target for Cancer Drug Development
Current Cancer Drug Targets SnoN: Bridging Neurobiology and Cancer Biology
Current Molecular Medicine Lipid Raft in Cardiac Health and Disease
Current Cardiology Reviews Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Current Pharmaceutical Design Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents
Current Medicinal Chemistry Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Vegan Diet: A Novel Trend in Healthy Living
Current Nutrition & Food Science Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology